Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
DOPA decarboxylase (DDC), also known as aromatic L-amino acid decarboxylase (AADC), is a pyridoxal 5'-phosphate (PLP)-dependent enzyme that catalyzes the decarboxylation of L-DOPA to dopamine and L-5-hydroxytryptophan to serotonin. The peripheral form refers to its activity outside the central nervous system. Peripheral DDC is targeted by inhibitors like carbidopa and benserazide to enhance levodopa's efficacy in treating Parkinson's disease by preventing its premature conversion to dopamine in the periphery, reducing side effects and increasing CNS availability.
Inhibition of peripheral DOPA decarboxylase, preventing the conversion of L-DOPA to dopamine outside the brain.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on DOPA Decarboxylase (Peripheral) (DDC).